A phase I/II study (NCT03356795) evaluates the safety and efficacy of CAR T cells in cervical cancer patients whose tumour cells express TAAs such as GD2, PSMA, Muc1 or mesothelin. The gene discussed is MUC1; the disease is cervical carcinoma.